Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Name: Kaimen Rigor review — Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Item: Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Rating: 94
Author: Alpha1

Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 5 high issues for “Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR

Read full text (PMC)

DOI

10.1038/s41591-025-04117-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/be014962-f4f0-4ba2-af46-4599f597f341" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/be014962-f4f0-4ba2-af46-4599f597f341/badge" alt="Kaimen Rigor review — 3.75★ (Adequate), 0 critical, 5 high issues for “Oral splicing modulator branaplam in Huntington&#39;s disease: a phase 2 randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a8c9e51f8eab6687517135facb521f12041066dc3e33d17eb1942e9fbdab3e8a

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR

Paper source

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

References were found (36) but none could be checked — every lookup failed or lacked a DOI.
No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Internal contradictions in the reported numbers
mediumArithmeticreviewer-assessedFull detail
The reported 1.49-fold accumulation in drug exposure does not match the Cmax and AUC values given in the same paragraph.
At week 1, mean C max was 26.1 ng ml −1 and AUC 0–168h was 1,880 h ng ml −1 , whereas at week 17, mean C max increased to 45.3 ng ml −1 and AUC 0–168h to 3,190 h ng ml −1 . The drug’s accumulation... showed a 1.49-fold increase in exposure for both parameters.
Resultsreviewer’s wording
02Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.
“The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.”
ResultsFind in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions · partly checked 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2b trial of branaplam in Huntington's disease, with strong scientific premise, robust design, and thorough ethical and reporting practices. The main weaknesses are minor reporting gaps: effect sizes are reported with SEs rather than CIs, the bespoke PK-PD modeling code is not shared, and several copyedit issues (unit inconsistencies, broken cross-references, typos) need correction.

This synthesis is based on two independent reviewer runs that largely agreed, with a divergence on data code availability (pass vs. warn) that was resolved by weighing the evidence for the missing PK-PD code. The statistics verification component could only recompute a subset of reported tests (none with test statistics/CIs), so the absence of detected errors does not confirm overall statistical correctness. The citation component found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

1 finding · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Prior work on HTT lowering and branaplam's mechanism is extensively cited (references 1–22). The rationale linking HTT lowering to disease modification is explicit, and the paper acknowledges limitations of prior safety observations (e.g., neurotoxicity in dogs) and addresses them through monitoring and study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is well-established: lowering mutant huntingtin is a promising strategy, and branaplam's mechanism is clearly described with extensive prior work cited.

Evidence

paraphrase[Introduction, paragraph 1–3]

“Branaplam was originally developed as a treatment for spinal muscular atrophy (SMA), in which it increases the amount of functional survival motor neuron protein produced by the SMN2 gene by modifying its mRNA splicing.”

paraphrase[Introduction, paragraph 3]

“Lowering the expression of total or mutant HTT in the brain is associated with a corresponding decrease in HTT levels in the cerebrospinal fluid (CSF), and a reduction of up to 40% in CSF mHTT has been shown to be safe and well tolerated in humans.”

paraphrase[Introduction, paragraph 4]

“Modulation of mRNA splicing nevertheless carries risks associated with off-target effects.”

PASSReviewer 2· 90% conf

The paper establishes a thorough scientific foundation, citing the HD/mHTT literature, branaplam's mechanism, and prior preclinical/clinical data, with an explicit rationale linking mHTT lowering to expected clinical benefit.

Evidence

“Branaplam had been shown to lower mHTT levels in neuroblastoma cells of individuals with HD and in an HD mouse model (BacHD)”

Introduction ¶3Find in source

“Safety studies of branaplam in dogs identified a potential risk of neurotoxicity, as evidenced by axonal degeneration of peripheral nerves and spinal cord”

Introduction ¶4Find in source

“This study aimed to identify a safe and well-tolerated oral dose of branaplam administered weekly that would lower CSF mHTT levels sufficiently to expect a clinical benefit.”

Introduction ¶6Find in source

Randomization was by Interactive Response Technology at the participant level, and the study is described as double-blind and placebo-controlled. The sample size calculation used MCP-Mod, assumed 35% mHTT lowering at the highest dose, applied a 50% SD inflation factor, and targeted more than 80% power at a one-sided 5% alpha. Inclusion criteria, an age cap, and the safety analysis set (all participants receiving at least one dose) are defined. Because the trial terminated early after cohort 1, planned inferential analyses were replaced by descriptive summaries, which the paper discloses.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The clinical trial design is robust: randomization via IRT, double-blind placebo control, pre-specified power analysis, inclusion/exclusion criteria, and outlier handling are all reported.

Evidence

“All eligible participants were randomized via Interactive Response Technology to one of the treatment arms.”

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting